

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/445, 31/535, 31/54, 31/41</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/22342 (43) International Publication Date: 26 June 1997 (26.06.97)</p>
<p>(21) International Application Number: PCT/DK96/00520 (22) International Filing Date: 10 December 1996 (10.12.96) (30) Priority Data: 1425/95 15 December 1995 (15.12.95) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK). (72) Inventor; and (75) Inventor/Applicant (for US only): OLSEN, Uffe, Bang [DK/DK]; Horsbred 111, DK-2625 Vallengbæk (DK). (74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: NOVEL METHOD</p> <div data-bbox="298 1146 1146 1528"> <p style="text-align: right;">(I)</p> </div> <p>(57) Abstract</p> <p>The present invention relates to the use of compounds of general formula (I) for reducing blood glucose and/or inhibit the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Hence the compound can be used in the treatment of insulin resistance related to NIDDM (non-insulin-dependent diabetes mellitus) or aging.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Novel Method

5

Field of the Invention

The present invention relates to the use of compounds of the general formula I for reducing blood glucose and/or inhibit the secretion, circulation or effect of insulin antagonizing peptides like CGRP or amylin. Hence the compound can be used in the treatment of patients suffering from NIDDM (non-insulin-dependent diabetes mellitus) in order to improve the glucose tolerance. The present invention also embraces pharmaceutical compositions comprising those compounds and methods of using the compounds and their pharmaceutical compositions.

15

Background of the Invention

The potent effects of CGRP on skeletal muscle glycogen synthase activity and muscle glucose metabolism, together with the notion that this peptide is released from the neuromuscular junction by nerve excitation, suggest that CGRP may play a physiological role in skeletal muscle glucose metabolism by directing the phosphorylated glucose away from glycogen storage and into the glycolytic and oxidative pathways (Rosetti et al. Am. J. Physiol. 264, E1-E10, 1993). This peptide may represent an important physiological modulator of intracellular glucose trafficking in physiological conditions, such as exercise, and may also contribute to the decreased insulin action and skeletal muscle glycogen synthase in pathophysiological conditions like NIDDM or aging-associated obesity (Melnik et al. Obesity Res. 3, 337-344, 1995) where circulating plasma levels of CGRP are markedly increased. Hence inhibition of release and/or activity of the neuropeptide CGRP may be useful in

20
25
30

the treatment of insulin resistance related to type 2 diabetes or aging.

In US Patent No. 4,383,999 and No. 4,514,414 and in EP 236342 as well as in EP 231996 some derivatives of N-(4,4-disubstituted-3-
5 butenyl)azaheterocyclic carboxylic acids are claimed as inhibitors of GABA uptake. In EP 342635 and EP 374801, N-substituted azaheterocyclic carboxylic acids in which an oxime ether group and vinyl ether group forms part of the N-substituent respectively are claimed as inhibitors of GABA uptake. In WO 9107389 and WO 9220658, N-substi-
10 tuted azacyclic carboxylic acids are claimed as GABA uptake inhibitors. EP 221572 claims that 1-aryloxyalkylpyridine-3-carboxylic acids are inhibitors of GABA uptake.

Further, WO 9518615 describes a method of treating neurogenic in-
15 flammation by means of the compounds claimed in WO 9220658. WO 9518793 discloses N-substituted azaheterocyclic carboxylic acids and esters thereof, methods for their preparation, compositions containing them and their use in treatment of hyperalgesic and/or inflammatory conditions.

20 In addition to the above cited references, US Patent No. 2,976,286 and British Patent No. 905,692 discloses 10-(dialkylaminoethoxyethyl)phenothiazines and US Patent No. 2,965,639 discloses 5-(dialkylaminoethoxyethyl)-10,11-dihydrodibenzo[b,f]azepines.
25 The compounds of US Patent No. 2,965,639 and British Patent No. 905,692 are disclosed for having antihistaminic, spasmolytic, anti-inflammatory, sedative and ganglion-blocking activity. The compounds of the present invention essentially differ from the compounds in US Patent No. 2,976,286, US Patent No. 2,965,639 and British Patent No.
30 905,692 by the amino acid moiety.


One object of the invention is to provide compounds which can effec-

tively be used in the treatment of insulin resistance in NIDDM or aging.

Description of the Invention

5 It has surprisingly been found that compounds of the general formula I below can be used in the treatment of insulin resistance related to NIDDM or aging.

Accordingly, the present invention relates to the use of compounds of
10 the general formula I



wherein

R¹ and R² independently are hydrogen, halogen, trifluoromethyl, C₁₋₈-alkyl or C₁₋₈-alkoxy; Y is >N-CH₂-, >CH-CH₂- or >C=CH- when s is 0, 1 or 2 or Y is >CH-CH=N- or >C=N- when s is 0 wherein only the under-

25 scored atom participates in the ring system;

X is -O-;

Z is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂CH₂CH₂-, -CH=CH- or -O-CH₂-;

R⁴ and R⁵ each represents hydrogen or may when m is 2 together represent a bond;

R⁶ is OH or C₁₋₈-alkoxy;

p is 0 or 1;

q is 0 or 1;

s is 0, 1 or 2;

r is 2, 3 or 4;

m is 1 or 2;

5 n is 1 when m is 1 or n is 0 when m is 2; or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for reducing blood glucose and/or inhibit the release and/or activity of CGRP, e.g. in the treatment of insulin resistance related to NIDDM or aging.

10

The compounds of formula I may exist as geometric and optical isomers and all isomers and mixtures thereof are included herein. Isomers may be separated by means of standard methods such as chromatographic techniques or fractional crystallization of suitable salts.

15

Preferably, the compounds of formula I exist as the individual geometric or optical isomers.

20

The compounds according to the invention may optionally exist as pharmaceutically acceptable acid addition salts or - when the carboxylic acid group is not esterified - as pharmaceutically acceptable metal salts or - optionally alkylated - ammonium salts.

25

Examples of such salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically acceptable inorganic or organic acid addition salts, and include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977) which are hereby incorporated by reference.

30

The term "C₁₋₆-alkyl" as used herein, alone or in combination, refers to a straight or branched, saturated hydrocarbon chain having 1-6 carbon

atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert.butyl, n-pentyl, neopentyl, n-hexyl and 2,2-dimethylpropyl.

5 The term "C₁₋₈-alkoxy" and "C₁₋₈-alkoxy" as used herein, alone or in combination, refers to a monovalent substituent comprising a C₁₋₈-alkyl group or C₁₋₈-alkyl group respectively, linked through an ether oxygen having its free valence bond from the ether oxygen, e.g. methoxy, ethoxy, propoxy, butoxy, pentoxy.

10 The term "halogen" means fluorine, chlorine, bromine and iodine.

As used herein, the term "patient" includes any mammal which could benefit from treatment of insulin resistance related to NIDDM or aging. The term particularly refers to a human patient, but is not intended to be
15 so limited.

Illustrative examples of compounds encompassed by the present invention include:

20 (R)-N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

25 N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-pyrrolidineacetic acid;

30 (R)-N-(2-(2-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-ethoxy)ethyl)-3-piperidinecarboxylic acid;

(R)-N-(2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)oxy)-

ethyl)-3-piperidinecarboxylic acid;

(R)-N-(2-(2-(5,6,7,12-Tetrahydrodibenz[b,g]azocin-12-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

5

(R)-N-(2-(2-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

10

(R)-N-(2-(2-(5,6,11,12-Tetrahydrodibenz[b,f]azocin-12-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

(R)-N-(2-(2-(10H-Phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

15

(R)-N-(2-(2-(2-Chloro-10H-phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

(S)-N-(2-(2-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

20

(R)-N-(2-(2-(10H-Phenoxazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

(R)-N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)ethyl)-3-piperidinecarboxylic acid;

25

(R)-N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

30

N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

- (R)-N-(3-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-ethoxy)-1-propyl)-3-piperidinecarboxylic acid;
- 5 (R)-N-(3-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)-1-propyl)-3-piperidinecarboxylic acid;
- (R)-N-(3-(2-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)-1-propyl)-3-piperidinecarboxylic acid;
- 10 (R)-N-(2-(((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methoxy)ethyl)-3-piperidinecarboxylic acid;
- (R)-N-(2-(((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid;
- 15 (R)-N-(2-((((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methylene)amino)oxy)ethyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(2-(5H-Dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;
- 20 (R)-1-(2-(2-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;
- (R)-1-(2-(2-(10,11-Dihydro-3-fluoro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;
- 25 (R)-1-(2-(2-(2,8-Difluoro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;
- 30 (R)-1-(2-(2-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid;

E/Z-(R)-1-(2-(2-(3-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)ethyl)-3-piperidinecarboxylic acid;

5 (R)-1-(2-(((3-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(((3,7-Dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid;

10 or a pharmaceutically acceptable salt thereof.

It has been demonstrated that the compounds of general formula I improves the glucose tolerance in diabetic ob/ob mice and that this may result from the reduced release of CGRP from peripheral nervous end-
15 ings. Hence the compounds of general formula I may be used in the treatment of NIDDM as well as aging-associated obesity. Experimentally this has been demonstrated by the subcutaneous administration of glucose into ob/ob mice with or without previous oral treatment with a compound of general formula I.

20


The compounds of general formula I may be prepared by using the methods taught in WO 9220658 which are hereby incorporated by reference.

25

The compounds of general formula I may be prepared by the following method:


Method A:

30



A compound of formula II wherein R^1 , R^2 , X, Y, Z, p, q, r and s are as defined above and W is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate, is allowed to react with an azaheterocyclic compound of formula III wherein R^4 , R^5 , R^6 , m and n are as defined above. This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, tetrahydrofuran or toluene in the presence of a base e.g. potassium carbonate and a catalyst, e.g. an alkali metal iodide at a temperature up to reflux temperature for the solvent used for e.g. 1 to 120 h. If esters have been prepared in which R^6 is alkoxy, compounds of formula I wherein R^6 is alkoxy, compounds of formula I wherein R^6 is OH are prepared by hydrolysis of the ester group, preferably at room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol for about 0.5 to 6 h.

30 Compounds of formula I, in which R⁴ and R⁵ does not represent a bond;
Z does not represent -S-, -CH=CH-, -CH=CH-CH₂- or CH₂-CH=CH-; and
Y represents >CH-CH₂-, are prepared by method B:

Method B:

A compound of formula IV wherein R^1 , R^2 , R^4 , R^5 , R^6 , r , s , p , q , m , n and Z are as defined above, except that R^4 and R^5 must not represent a bond and Z must not be $-S-$, $-CH=CH-$, $-CH=CH-CH_2-$ or $-CH_2-CH=CH-$, is hydrogenated to give I in which R^4 , R^5 and Z are as defined above. This reduction is carried out in a solvent such as methanol in the presence of a catalyst eg. palladium on carbon at a pressure of eg. 1 to 10 atm. and reaction time about 0.5 to 18 h.

If esters have been prepared in which R^6 is alkoxy, compounds of formula I wherein R^6 is OH are prepared by hydrolysis of the ester group, preferably at room temperature in a mixture of an aqueous alkali metal hydroxide solution and an alcohol such as methanol or ethanol for about 0.5 to 6 h.

Compounds of formula II and III are prepared by methods familiar to those skilled in the art.

Under certain circumstances it is necessary to protect the intermediates used in the above methods e.g. a compound of formula III with suitable protecting groups. The carboxylic acid group can for example be esterifi-

ed. Introduction and removal of such groups is described in "Protective Groups in Organic Chemistry" J.F.W. McOrnie ed. (New York, 1973).

Pharmacological Methods

5

The reduction of plasma levels of CGRP in diabetic mice treated with a compound of the general formula I is described in the following.

10

ob/ob female mice, 16 weeks of age, where injected glucose (2g/kg) subcutaneously. At times hereafter blood glucose was determined in tail venous blood by the glucose oxidase method. At the end of the study the animals were decapitated and trunk blood collected. Immuno-reactive CGRP was determined in plasma by radio-immuno-assay. Two groups of animals were used. The one group was vehicle treated, where-
as the other group received a compound of formula I via drinking water (100 mg/l) for five days before the test.

15

For the above indications the dosage will vary depending on the compound of general formula I employed, on the mode of administration and on the therapy desired. However, in general, satisfactory results are obtained with a dosage of from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of compounds of formula I, conveniently given from 1 to 5 times daily, optionally in sustained release form. Usually, dosage forms suitable for oral administration comprise from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg of the compounds of formula I admixed with a pharmaceutical carrier or diluent.

20

25

The compounds of formula I may be administered in pharmaceutically acceptable acid addition salt form or where possible as a metal or a lower alkylammonium salt. Such salt forms exhibit approximately the same order of activity as the free base forms.

30

This invention also relates to pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof and, usually, such compositions also contain a pharmaceutical carrier or diluent. The compositions containing the compounds of this invention
5 may be prepared by conventional techniques and appear in conventional forms, for example capsules, tablets, solutions or suspensions.

The pharmaceutical carrier employed may be a conventional solid or liquid carrier. Examples of solid carriers are lactose, terra alba, sucrose,
10 talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Examples of liquid carriers are syrup, peanut oil, olive oil and water.

Similarly, the carrier or diluent may include any time delay material known to the art, such as glyceryl monostearate or glyceryl distearate,
15 alone or mixed with a wax.

If a solid carrier for oral administration is used, the preparation can be tabletted, placed in a hard gelatin capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will
20 vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

25 Generally, the compounds of this invention are dispensed in unit dosage form comprising 50-200 mg of active ingredient in or together with a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is 1-500
30 mg/day, e.g. about 100 mg per dose, when administered to patients, e.g. humans, as a drug.

A typical tablet which may be prepared by conventional tableting techniques contains

Core:

5	Active compound (as free compound or salt thereof)	100 mg
	Colloidal silicon dioxide (Areosil®)	1.5 mg
	Cellulose, microcryst. (Avicel®)	70 mg
	Modified cellulose gum (Ac-Di-Sol®)	7.5 mg
10	Magnesium stearate	

Coating:

	HPMC	approx.	9 mg
	*Mywacett® 9-40 T	approx.	0.9 mg

15

*Acylated monoglyceride used as plasticizer for film coating.

20

The route of administration may be any route which effectively transports the active compound to the appropriate or desired site of action, such as oral or parenteral e.g. rectal, transdermal, subcutaneous, intranasal, intramuscular, topical, intravenous, intraurethral, ophthalmic solution or an ointment, the oral route being preferred.

EXAMPLES

The process for preparing compounds of formula I is further illustrated in the following examples, which, however, are not to be construed as limiting.

5

Hereinafter, TLC is thin layer chromatography and THF is tetrahydrofuran, CDCl₃ is deuterio chloroform and DMSO-d₆ is hexadeuterio dimethylsulfoxide. The structures of the compounds are

confirmed by either elemental analysis or NMR, where peaks assigned to characteristic protons in the title compounds are presented where appropriate. NMR shifts (δ) are given in parts per million (ppm). M.p. is melting point and is given in °C. Column chromatography was carried out using the technique described by W.C. Still et al, J. Org. Chem. 1978, 43, 2923-2925 on Merck silica gel 60 (Art. 9385). Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.

EXAMPLE 1

(R)-N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

A mixture of sodium hydride (0.40 g, 0.010 mol, 60% oil dispersion) and 10,11-dihydro-5H-dibenz[b,f]azepine (1.95 g, 0.010 mol) in dry dibutylether (30 ml) was heated at reflux temperature for 3.5 h under an atmosphere of nitrogen. The reaction mixture was cooled to 100°C and bis-2-chloro-ethyl ether (4.7 ml) was added and the mixture was heated at reflux temperature for 16 h. The reaction mixture was cooled and water (50 ml) was added.

The mixture was extracted with toluene (100 ml). The organic extract was dried over sodium sulphate and the solvent evaporated in vacuo to give 2.8 g of an oily residue containing 2-chloro-1-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethane. To this oil was added ethyl (R)-3-piperidinecarboxylate (3.0 g, 0.019 mol) and the mixture was heated at 150°C for 1.5 h. The reaction mixture was allowed to cool to 80°C and toluene (100 ml) was added. The mixture was then allowed to cool to room temperature and a solution of potassium carbonate (1.4 g) in water (100 ml) was added. The phases were separated and the organic phase

was washed successively with water, an aqueous sodium acetate solution (pH 5) and an aqueous citric acid solution (pH 5). The organic phase was then extracted with a 5% aqueous citric acid solution (50 ml). The acidic (pH 1) aqueous extract was washed with toluene (2x50 ml) and then a 4 N sodium hydroxide solution was added until pH 6-7. The aqueous mixture was extracted with toluene and the organic extract was treated with charcoal and dried over sodium sulphate. The solvent was evaporated in vacuo to give 2.1 g (50%) of (R)-N-(2-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.20$ (SiO_2 ; n-heptane/THF = 7:3).

The above ester was dissolved in ethanol (10 ml) and a 12 N sodium hydroxide solution (1.25 ml) was added. The mixture was stirred at room temperature for 4 h. A concentrated hydrochloric acid solution was added until pH 1. Dichloromethane (300 ml) was added followed by water until the solid material was dissolved. The phases were separated and the organic phase was dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue, which was re-evaporated twice with acetone and then recrystallized from acetone. This afforded 1.4 g (65%) of the title compound.

M.P. 185-186°. Calculated for $\text{C}_{24}\text{H}_{31}\text{ClN}_2\text{O}_3 \cdot \frac{1}{4}\text{H}_2\text{O}$:

C, 66.9%; H, 7.3%; Cl, 8.2%; N, 6.5%; Found:

C, 67.0%; H, 7.5%; Cl, 8.2%; N, 6.3%.

EXAMPLE 2a

(R)-N-(2-(2-(10H-Phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

Phenothiazine (3.8 g, 19 mmol) was added to a suspension of sodium hydride (0.92 g, 23 mmol, 60% oil dispersion) in dry dibutylether (25 ml)

under an atmosphere of nitrogen. The mixture was heated at 135°C for 1 h and then cooled to approximately 100°C. 2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethylchloride (8 g, 38 mmol) was added in one portion and the mixture was heated overnight at 110°C. The reaction
5 mixture was poured into water (250 ml) and extracted with dichloromethane (3x50 ml) and diethyl ether (50 ml). The combined organic extracts were washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo leaving an oil, which was submitted to column chromatography using dichloromethane as eluent.
10 Collecting the proper fractions afforded 3.9 g of crude 10-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-10H-phenothiazine. TLC: r_f = 0.72 (SiO_2 ; dichloromethane/methanol = 19:1).

A mixture of crude 10-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-
15 10H-phenothiazine (3.8 g, 10 mmol), 2-propanol (50 ml) and a 4 M aqueous sulfuric acid solution (8 ml) was heated at 60°C for 3 h and then left overnight at room temperature. The reaction mixture was poured into a mixture of water (500 ml) and a 4 N sodium hydroxide solution (17 ml). The mixture was extracted with diethyl ether (150 ml)
20 and the organic extract was washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give 1.5 g of crude 2-(2-(10H-phenothiazin-10-yl)ethoxy)ethanol. TLC: r_f = 0.52 (SiO_2 ; dichloromethane/methanol = 19:1).

25 A well-stirred mixture of the above alcohol (1.5 g, 5.2 mmol), triethylamine (1.8 ml) and toluene (20 ml) placed under an atmosphere of nitrogen was cooled on an ice-bath. A solution of methanesulfonyl chloride (1.5 g, 10.4 mmol) in toluene (5 ml) was added within 15 minutes. Stirring was continued for 45 minutes on an ice-bath and then
30 for 30 minutes at room temperature. Water (15 ml) was added and the mixture was stirred at room temperature for 15 minutes. The phases were separated and the aqueous phase was extracted with toluene (20

ml). The combined organic extracts were washed with a 5% sodium bicarbonate solution, brine and then dried over sodium sulphate. The solvent was evaporated in vacuo to give an oil, which was dissolved in toluene (30 ml). To this solution was added potassium carbonate (2.5 g, 18.3 mmol) and ethyl (R)-3-piperidinecarboxylate tartrate (3.2 g, 10.4 mmol) and the suspension was heated at reflux temperature for 3 days. The cooled reaction mixture was filtered and the solid washed with a small portion of toluene. The solvent was evaporated from the filtrate in vacuo to give a residue, which was dissolved in a mixture of ethyl acetate (30 ml) and water (30 ml). A 34% aqueous solution of tartaric acid was added until pH 4. The phases were separated and the aqueous phase was extracted with ethyl acetate (15 ml). To the combined organic phases were added water (10 ml) and a 34% aqueous solution of tartaric acid (3.5 ml). The phases were separated and the organic phase was extracted with a mixture of water (10 ml) and a 34% aqueous solution of tartaric acid (2 ml). The acidic aqueous phases are combined and washed with ethyl acetate (15 ml). All the organic phases were discarded and to the acidic aqueous phase was added ethyl acetate (50 ml) and water (50 ml). A 4 N sodium hydroxide solution was added until pH 8.5 and the phases were separated. The aqueous phase was extracted with ethyl acetate (15 ml) and the combined organic phases were washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give 0.8 g of (R)-N-(2-(2-(10H-phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.20$ (SiO₂; dichloromethane/methanol/acetic acid = 20:2:1).

The above ester (0.8 g, 1.8 mmol) was dissolved in ethanol (15 ml) and a 4 N sodium hydroxide solution (2 ml) was added. The mixture was stirred vigorously at room temperature for 4 h. The solvent was evaporated in vacuo to give an oily residue. Dichloromethane (100 ml) was added and the mixture was cooled on an ice-bath. A concentrated hydrochloric acid solution (1 ml) was added. The mixture was stirred

vigorously for a few minutes and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was re-evaporated with dichloromethane, dissolved in dichloromethane and left overnight at 4°C.

5 The solid formed was isolated by filtration to give 0.6 g of the title compound as a solid.

M.P. 188-189°C. Calculated for $C_{22}H_{27}ClN_2O_3S$:

C, 60.7%; H, 6.3%; N, 6.4%; Found:

10 C, 60.4%, H, 6.3%; N, 6.3%.

The following compounds were prepared by a similar procedure:

EXAMPLE 2b

15

(R)-N-(2-(2-(10H-Phenoxazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

20 After an alkaline hydrolysis similar to that described above, the dichloromethane extract was dried over sodium sulphate and evaporated in vacuo. The foamy residue was heated to reflux temperature with acetone, cooled, filtered and dried to give 1.7 g of the title compound as a solid.

25

M.P. 161-164°C. Calculated for $C_{22}H_{28}ClN_2O_4$:

C, 63.1%; H, 6.5%; N, 6.7%; Found:

C, 63.1%; H, 6.6%; N, 6.4%.

30

EXAMPLE 2c

(R)-N-(2-(2-(2-Chloro-10H-pheno-
thiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

5

After an alkaline hydrolysis similar to that described above, the dichloromethane extract was dried over magnesium sulphate and evaporated in vacuo. The foamy residue was heated in acetone, cooled, filtered and dried to give 2.3 g of the title compound as an amorphous solid.

10

M.P. 75°C. Calculated for $C_{22}H_{25}ClN_2O_3S \cdot HCl \cdot H_2O$:

C, 54.2%; H, 5.8%; N, 5.8%; Found:

C, 54.8%; H, 5.7%; N, 5.5%.

15

EXAMPLE 2d

(S)-N-(2-(2-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

20

After an alkaline hydrolysis similar to that described above, the dichloromethane extract was dried over magnesium sulphate and evaporated in vacuo. The residue was re-evaporated twice with acetone and dissolved in acetone (20 ml) and left for crystallization. The solid formed was isolated by filtration and dried to give 1.9 g of the title compound as an amorphous solid.

25

M.P. 115°C. Calculated for $C_{23}H_{28}ClF_3N_2O_3S$:

C, 54.9%; H, 5.2%; N, 5.6%; Found:

C, 54.7%; H, 5.4%; N, 5.4%.

30

1H NMR (DMSO- d_6) δ 4.20 (t, 2H).

EXAMPLE 2e

(R)-1-(2-(2-(5H-Dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

- 5 M.P. 169°C. Calculated for $C_{24}H_{28}ClN_2O_3$:
C, 67.2%; H, 6.8%; N, 6.5%; Cl, 8.3%; Found:
C, 66.9%; H, 6.9%; N, 6.3%; Cl, 8.1%.

EXAMPLE 2f

10

(R)-1-(2-(2-(2,8-Dibromo-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

- 15 M.P. 163-164°C. Calculated for $C_{24}H_{28}Br_2ClN_2O_3$:
C, 49.0%; H, 5.0%; N, 4.8%; Found:
C, 48.8%; H, 5.2%; N, 4.6%.

EXAMPLE 2g

20

(R)-1-(2-(2-(10,11-Dihydro-3-fluoro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

- 25 Amorph. solid. Calculated for $C_{24}H_{30}ClFN_2O_3 \cdot C_3H_8O$:
C, 64.0%; H, 7.2%; N, 5.5%; Cl, 7.0%; Found:
C, 63.5%; H, 7.1%; N, 5.7%; Cl, 7.1%.

EXAMPLE 2h

30

(R)-1-(2-(2-(2,8-Difluoro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

- 35 M.p. 153-155°C. Calculated for $C_{24}H_{29}ClF_2N_2O_3 \cdot 1/4H_2O$:
C, 61.1%; H, 6.3%; N, 5.9%; Found:

C, 61.5%; H, 6.5%; N, 5.9%.

EXAMPLE 2i

5 (R)-1-(2-(2-(3-Chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

Amorph. solid.

10 ¹H NMR (DMSO-d₆) δ 3.50 (t, 2H); 3.58 (s, 2H); 3.92 (t, 2H).

EXAMPLE 3a

15 (R)-N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

A solution of 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-one (9.4 g, 0.045 mol) in dry THF (100 ml) was placed under an atmosphere of
20 nitrogen. A solution of vinylmagnesium bromide in THF (100 ml, 0.5 M) was added in such a rate to keep the reaction temperature at 30-35°C. When addition was complete the mixture was heated at 50-60°C for 1.5 h. The reaction mixture was cooled on an ice-bath and a solution of ammonium chloride (10 g) in water (50 ml) was carefully added. Diethyl
25 ether (100 ml) was added and the phases were separated. The aqueous phase was extracted with diethyl ether (100 ml) and the combined organic phases were dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue which was re-evaporated twice
30 with dichloromethane to give 11.8 g of crude 5-ethenyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ol.

The above crude alcohol (9.2 g) was dissolved in dichloromethane (100 ml) and the mixture was placed on an ice-bath. A solution of trimethylsilyl bromide (6.6 g, 0.043 mol) in dichloromethane (50 ml) was

added dropwise within 30 minutes. When addition was complete the mixture was stirred at room temperature for 45 minutes. Icewater (50 ml) and a saturated aqueous sodium bicarbonate solution (200 ml) was added. The phases were separated and the organic phase was dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue, which was re-evaporated with cyclohexane. This afforded 10.5 g of crude 5-(2-bromoethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene.

A solution of n-butyllithium in hexanes (12 ml, 2.5 M) was added dropwise to ice-cooled ethylene glycol (25 ml) under an atmosphere of nitrogen. When addition was complete the mixture was stirred at room temperature for 30 minutes. A solution of the above crude bromide (7.1 g) in cyclohexane (20 ml) was added in one portion and the hexanes were removed by vigorous stirring and a strong nitrogen flow. Then the reaction mixture was stirred at room temperature for 68 h. Water (30 ml) was added and the mixture was extracted with ethyl acetate (3x50 ml). The combined organic extracts were dried over sodium sulphate and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (150 g) using a mixture of THF and n-heptane (3:7) as eluent. Collecting the proper fractions afforded 2.4 g of 5-(2-(2-hydroxyethoxy)ethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene as an oil. TLC: $r_f = 0.18$ (SiO_2 ; THF/n-heptane = 3:7).

A solution of the above alcohol (3.7 g, 13.2 mmol) in dry THF (40 ml) was placed under an atmosphere of nitrogen and placed on an ice-bath. A solution of n-butyllithium in hexanes (3.7 ml, 2.5 M) was added dropwise and the mixture was stirred for another 15 minutes. p-Toluenesulfonyl chloride (2.5 g, 13.2 mmol) was added in one portion and the mixture was stirred on an ice-bath for 1 h. The solvent was evaporated in vacuo keeping the bath temperature below 20°C. The

residue was dissolved in acetone (25 ml) and ethyl (R)-3-piperidinecarboxylate (3.1 g, 19.8 mmol) and potassium carbonate (3.3 g, 24.0 mmol) were added. The mixture was stirred at room temperature for 140 h. The mixture was filtered and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (200 g) using a mixture of ethyl acetate and n-heptane (1:1) as eluent. Collecting the proper fractions afforded 1.7 g of (R)-N-(2-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.19$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

The above ester (1.7 g, 4.1 mmol) was dissolved in ethanol (15 ml) and a 4 N sodium hydroxide solution (3.5 ml) was added. The mixture was stirred vigorously at room temperature for 5 h. Dichloromethane (300 ml) was added followed by a 4 N hydrochloric acid solution until pH 1. The mixture was stirred vigorously for a few minutes and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was re-evaporated twice with acetone, once with ethyl acetate and once with diethyl ether to give 1.7 g of the title compound as a solid which was recrystallized from acetone.

M.P. 157-159°C. Calculated for $\text{C}_{25}\text{H}_{30}\text{ClNO}_3$:

C, 70.2%; H, 7.1%; N, 3.3%; Found:

C, 70.1%; H, 7.1%; N, 3.2%.

By a similar procedure as described in Example 3a the following compound has been prepared:

EXAMPLE 3b

E/Z-(R)-1-(2-(2-(3-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

- 5 Amorph. solid. Calculated for $C_{25}H_{30}Cl_2NO_3 \cdot H_2O$:
C, 62.5%; H, 6.5%; N, 2.9%; Found:
C, 62.7%; H, 6.5%; N, 2.7%.
 1H NMR (DMSO- d_6) δ Minor isomer: 6.02 (t, 1H, -CH=); Major isomer:
6.05 (t, 1H, -CH=).

10

EXAMPLE 4

(R)-N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

15

The acid prepared in Example 3 (0.2 g, 0.5 mmol) was dissolved in methanol (10 ml) and stirred under an atmosphere of hydrogen for 16 h at room temperature in the presence of 10% palladium on carbon catalyst (50% aqueous paste). The mixture was filtered and the solvent was
20 evaporated in vacuo to give an oily residue, which was re-evaporated from acetone and then crystallized from acetone (10 ml). This afforded 0.13 g (65%) of the title compound.

- 25 M.P. 147-148°C.
 1H NMR (DMSO- d_6) δ 4.24 (brs, 1H).

EXAMPLE 5

- 30 (R)-N-(3-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)-1-propyl)-3-piperidinecarboxylic acid hydrochloride
-

- A solution of n-butyllithium in hexanes (16.8 ml, 2.5 M) was added
35 dropwise to ice-cooled propylene glycol (25 ml) under an atmosphere of

nitrogen. When addition was complete the mixture was stirred at room temperature for 15 minutes. A solution of crude 5-(2-bromoethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (10.1 g, prepared as described in Example 3a) was added in one portion and the reaction mixture was stirred at room temperature for 42 h. Water (40 ml) was added and the mixture was extracted with ethyl acetate (3x75 ml). The combined organic extracts were washed with water (15 ml), dried over sodium sulphate and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (200 g) using a mixture of THF and n-heptane (3:7) as eluent. Collecting the proper fractions afforded 4.2 g of 5-(2-(3-hydroxypropyloxy)ethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene as an oil. TLC: $r_f = 0.18$ (SiO_2 ; THF/n-heptane = 3:7).

A solution of the above alcohol (4.2 g, 14.3 mmol) in dry THF (30 ml) was placed under an atmosphere of nitrogen and placed on an ice-bath. A solution of n-butyllithium in hexanes (5.7 ml, 2.5 M) was added dropwise within 15 minutes and the mixture was stirred for another 15 minutes. p-Toluenesulfonyl chloride (2.7 g, 14.0 mmol) was added in one portion and the mixture was stirred at room temperature for 30 minutes. The solvent was evaporated in vacuo keeping a low bath temperature. The oily residue was dissolved in acetone (25 ml) and ethyl (R)-3-piperidinecarboxylate (3.3 g, 21.0 mmol) and potassium carbonate (3.5 g, 25.0 mmol) were added. The mixture was stirred at room temperature for 120 h. The mixture was filtered and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (100 g) using a mixture of ethyl acetate and n-heptane (2:3) as eluent. Collecting the proper fractions afforded 3.0 g of (R)-N-(3-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)-1-propyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.19$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

The above ester (2.5 g, 5.8 mmol) was dissolved in ethanol (15 ml) and a 4 N sodium hydroxide solution (4.3 ml) was added. The mixture was stirred vigorously at room temperature for 5 h. A 4 N hydrochloric acid solution was added until pH 1 followed by dichloromethane (400 ml).

5 The mixture was stirred vigorously for a few minutes and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was evaporated twice with acetone, once with ethyl acetate, dissolved in acetone (15 ml) and left for crystallization. This afforded 1.9 g of the title compound as a
10 solid.

M.P. 78-80°C. Calculated for $C_{26}H_{32}ClNO_3 \cdot \frac{3}{4}H_2O$:

C, 68.6%; H, 7.4%; N, 3.1%; Cl, 7.8%; Found:

C, 68.3%; H, 7.3%; N, 3.0%; Cl, 7.8%.

15

EXAMPLE 6

(R)-N-(3-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)-1-
20 -propyl)-3-piperidinecarboxylic acid hydrochloride

20

The acid prepared in Example 5 (0.5 g, 1.1 mmol) was dissolved in methanol (15 ml) and stirred under an atmosphere of hydrogen for 8 h at room temperature in the presence of 10 % palladium on carbon catalyst
25 (50 % aqueous paste). The mixture was filtered and the solvent was evaporated in vacuo to give an oily residue which was re-evaporated from acetone and then crystallised from a mixture of acetone and ethyl acetate. This afforded 0.3 g (60%) of the title compound as an amorphous solid.

30

M.P. 80-81°C.

1H NMR (DMSO- d_6) δ 4.21 (brs, 1H).

EXAMPLE 7a

(R)-N-(2-(((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

5 A mixture of 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-one (9.4 g, 45 mmol) and hydroxylamine hydrochloride (6.3 g, 90 mmol) pyridine (60 ml) was heated at reflux temperature for 48 h. Another portion of
10 hydroxylamine hydrochloride (6.3 g, 90 mmol) was added and heating at reflux temperature was continued for another 24 h. The reaction mixture was allowed to cool and the solvent was evaporated in vacuo to give an oily residue, which was dissolved in a mixture of ethyl acetate (100 ml) and a 10% aqueous citric acid solution (100 ml). The phases were
15 separated and the aqueous phase was extracted with ethyl acetate (50 ml). The combined organic phases were extracted with an aqueous citric acid solution (50 ml). The separated organic phase was washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo to a solid residue, which was recrystallized from cyclohexane.
20 This afforded 5.4 g of the oxime derivative as a solid. TLC: $r_f = 0.61$ (SiO_2 ; dichloromethane/methanol = 19:1).

To an ice-cooled mixture of the above oxime derivative (1.0 g, 4.5 mmol), tetrabutylammonium bromide (0.15 g, 0.5 mmol) and 1,2-
25 dibromoethane (3.8 ml) was added a 12 M sodium hydroxide solution (5 ml). The reaction mixture was stirred vigorously for 4.5 h. A 2 M hydrochloric acid solution (50 ml) and diethyl ether (25 ml) was added. The phases were separated and the aqueous phase was extracted with diethyl ether (25 ml). The combined organic phases were washed with a
30 5% sodium bicarbonate solution, brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue, which was re-evaporated successively with ethanol, toluene, methanol and dichloromethane. This afforded 1.4 g of the crude 2-(((10,11-dihydro-

5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethylbromide as an oil.
TLC: $r_f = 0.65$ (SiO_2 ; dichloromethane).

To a solution of 2-(((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethylbromide (1.4 g, 4.2 mmol) in methyl isobutylketone (40 ml) was added potassium carbonate (4.7 g, 34 mmol) and ethyl (R)-3-piperidinecarboxylate tartrate (2.6 g, 8.5 mmol) and the suspension was heated at reflux temperature for 3 days. The cooled reaction mixture was filtered and the solvent was evaporated from the filtrate in vacuo.

The oily residue was dissolved in a mixture of ethyl acetate (50 ml) and water (50 ml). A 34% aqueous tartaric acid solution was added until pH 4. The phases were separated and the aqueous phase was extracted with ethyl acetate (25 ml). The combined organic phases were extracted with a 34% aqueous tartaric acid solution (2x5 ml) and the organic extracts were discarded. The acidic aqueous phases were combined, diluted three times with water and ethyl acetate (40 ml) was added. A 4 N sodium hydroxide solution was added until pH 7 and the phases were separated. The organic phase was washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give 1 g of (R)-N-(2-(((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.39$ (SiO_2 ; dichloromethane/methanol/acetic acid = 20:2:1).

The above ester (1.0 g, 3.0 mmol) was dissolved in ethanol (25 ml) and a 4 N sodium hydroxide solution (3.4 ml) was added. The mixture was stirred vigorously at room temperature for 22 h. The solvent was evaporated in vacuo to give an oily residue. Dichloromethane (75 ml) was added and the mixture was cooled on an ice-bath. A concentrated hydrochloric acid solution (1.6 ml) was added. The mixture was stirred vigorously for a few minutes and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was re-evaporated three times with

dichloromethane and once with acetone to give 0.95 g of the title compound as a foam.

M.P. 119°C.

5 ^1H NMR (DMSO- d_6) δ 4.5-4.6 (m, 2H).

By a similar procedure as described in Example 7a the following compounds have been prepared:

10 EXAMPLE 7b

(R)-1-(2-(((3-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

15

M.P. 208-210°C.

^1H NMR (DMSO- d_6) δ 4.55 (brs, 2H, $-\text{OCH}_2-$).

EXAMPLE 7c

20

(R)-1-(2-(((3,7-Dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)amino)oxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

25 M.P. 143-144°C. Calculated for $\text{C}_{23}\text{H}_{28}\text{Cl}_3\text{N}_2\text{O}_3$:

C, 57.1%; H, 5.2%; N, 5.8%; Found:

C, 57.5%; H, 5.6%; N, 5.5%.

EXAMPLE 8

30

(R)-N-(2-(((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methoxy)-ethyl)-3-piperidinecarboxylic acid hydrochloride

35

To a solution of

10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-carboxaldehyde (11.3 g, 51 mmol, prepared in a similar way as described in Acta Chem. Scand.

1978, B33, 100-103) and tetrabutylammonium bromide (1.64 g, 5.1 mmol) in dichloromethane (100 ml) was added 1,2-dibromoethane (62 ml) and a 12 M sodium hydroxide solution (100 ml). The reaction mixture was stirred vigorously overnight and dichloromethane (100 ml) was added. The phases were separated and the aqueous phase was extracted with dichloromethane (100 ml). The combined organic phases were washed with a 0.2 M hydrochloric acid solution (100 ml), brine (25 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo to give 14.1 g of 2-((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methoxy)ethylbromide. TLC: $r_f = 0.48$ (SiO_2 ; ethyl acetate/n-heptane = 1:4).

To a solution of 2-((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methoxy)ethylbromide (14.0 g, 42.5 mmol) in acetone (100 ml) was added potassium carbonate (23.5 g, 170 mmol), potassium iodide (0.7 g) and ethyl (R)-3-piperidinecarboxylate tartrate (19.6 g, 64 mmol).

The suspension was stirred at room temperature for 3 days. The reaction mixture was filtered and the solvent was evaporated from the filtrate in vacuo. The oily residue was dissolved in ethyl acetate (150 ml). A 34% aqueous tartaric acid solution (100 ml) was added and pH was adjusted to 2.5 with a 4 M aqueous sodium hydroxide solution. The phases were separated and the organic phase was washed with a 2.5% aqueous solution of sodium bicarbonate (100 ml) and a 5% aqueous sodium bicarbonate solution (25 ml). The combined aqueous phases were extracted with ethyl acetate (100 ml). The combined organic phases were dried over magnesium sulphate. The solvent was evaporated in vacuo to give 12.0 g of (R)-N-(2-((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)methoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.45$ (SiO_2 ; dichloromethane/methanol/ acetic acid

= 20:2:1).

The above ester (2.0 g, 4.9 mmol) was dissolved in ethanol (20 ml) and a 4 N sodium hydroxide solution (4.9 ml) was added. The mixture was stirred at 50°C for 2 h. Water (10 ml) was added and ethanol was evaporated in vacuo to give an aqueous residue. A 4 M aqueous hydrochloric acid solution (6.2 ml) was added followed by dichloromethane (50 ml). The phases were separated and the aqueous phase was extracted with dichloromethane (50 ml). The combined organic phases were washed with water (10 ml) and then dried over magnesium sulphate. The solvent was evaporated in vacuo and the residue dried in vacuo to give 1.71 g of the title compound as a solid.

M.P. 111-114°C (dec.). Calculated for $C_{24}H_{28}ClNO_3 \cdot \frac{1}{2}H_2O$:
C, 70.6%; H, 7.2%; N, 3.3%; Cl, 4.2%; Found:
C, 70.2%; H, 7.0%; N, 3.2%; Cl, 4.5%.

EXAMPLE 9

N-(2-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride

A solution of 5-(2-(2-hydroxyethoxy)ethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (2.4 g, 8.2 mmol, prepared as described in Example 3) in dioxane (25 ml) was hydrogenated at 10 atm. for 16 h at room temperature in the presence of 10% palladium on carbon catalyst (50% aqueous paste). The mixture was filtered and the solvent was evaporated in vacuo to give an oily residue, which was re-evaporated from carbontetrachloride. This afforded 2.2 g 2-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethanol as an oil.

A solution of the above alcohol (2.2 g, 7.4 mmol) in dry THF (20 ml)

was placed under an atmosphere of nitrogen and placed on an ice-bath. A solution of n-butyllithium in hexanes (3.0 ml, 2.5 M) was added dropwise and the mixture was stirred for another 15 minutes.

5 Methanesulfonyl chloride (0.85 g, 7.4 mmol) was added in one portion and the mixture was stirred on an ice-bath for 45 minutes. The solvent was evaporated in vacuo and the residue was dissolved in acetone (25 ml). Ethyl 1,2,5,6-tetrahydro-3-pyridinecarboxylate hydrochloride (1.5 g, 7.8 mmol) and potassium carbonate (2.5 g, 18 mmol) were added. The mixture was stirred at reflux temperature for 16 h. The mixture was
10 filtered and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (150 g) using a mixture of ethyl acetate and n-heptane (1:1) as eluent. Collecting the proper fractions afforded 1.3 g of N-(2-(2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)ethoxy)ethyl)-1,2,5,6-tetrahydro-3-
15 pyridinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.14$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

The above ester (1.3 g, 3.1 mmol) was dissolved in ethanol (10 ml) and a 4 N sodium hydroxide solution (2.3 ml) was added. The mixture was
20 stirred at room temperature for 4 h. A 4 N hydrochloric acid solution was added until pH 1. Dichloromethane (400 ml) was added and the mixture was stirred vigorously for a few minutes and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was re-evaporated with acetone,
25 dissolved in acetone (50 ml) and left for crystallization. This afforded 0.45 g of the title compound as a solid.

M.P. 154-155°C. Calculated for $\text{C}_{25}\text{H}_{30}\text{ClNO}_3$:

C, 70.2%; H, 7.1%; N, 3.3%; Cl, 8.3%; Found:

30 C, 70.1%; H, 7.2%; N, 3.1%; Cl, 8.2%.

EXAMPLE 10

(R)-N-(2-((3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)oxy)-ethyl)3-piperidinecarboxylic acid hydrochloride

5

To a solution of 10,11-dihydro-5H-dibenz[b,f]azepine (8.1 g, 40 mmol) in dry dibutylether (60 ml) kept under an atmosphere of nitrogen, NaH (1.6 g, 40 mmol, 60 % oil dispersion) was carefully added. The reaction mixture was heated at reflux temperature for 4 h and then allowed to cool to 80°C. 3-Bromo-1-propyl tetrahydro-2-pyranyl ether (10.7 g, 48 mmol) was added and the mixture was heated at reflux temperature for 16 h. To the cooled reaction mixture was added water (20 ml) and the phases were separated. From the organic phase the solvent was evaporated and the residue was dissolved in a mixture of MeOH (150 ml) and a 4 N aqueous HCl solution (50 ml). The mixture was heated at reflux temperature for 15 minutes and then stirred for 1 h at RT. Water (250 ml) was added and the mixture was extracted with ethyl acetate (2 x 200 ml). The combined organic extracts was dried (Na₂SO₄), filtered and the solvent evaporated in vacuo. This afforded a residue which was submitted to chromatography on silica gel (200 g) using a mixture of n-heptane and ethyl acetate (3:2) as eluent to give 5.5 g of 3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propanol as an oil. TLC: *rf* = 0.30 (SiO₂; n-heptane/ethyl acetate = 1:1).

10

15

20

25

30

A mixture of NaH (0.40 g, 10 mmol, 60% oil dispersion), 3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propanol (2.5 g, 10 mmol) and dry dibutylether (25 ml) was stirred for 16 h at reflux temperature under a nitrogen atmosphere. The reaction mixture was allowed to cool and 2-bromoethyl tetrahydro-2-pyranyl ether (2.5 g, 12 mmol) was added. Then the mixture was heated to reflux temperature and kept there for 16 h. To the cooled mixture was added water (10 ml) and the phases were separated. From the organic phase the solvent was evaporated in vacuo to give a residue which was submitted to chromatography on silica gel

(200 g) using a mixture of n-heptane and ethyl acetate (7:3) as eluent. This afforded 1.5 g of the tetrahydro-2-pyranyl intermediate. TLC: r_f = 0.55 (SiO_2 ; n-heptane/ethyl acetate = 1:1). This intermediate was dissolved in a mixture of methanol (30 ml) and a 4 N aqueous hydrochloric acid solution (15 ml) and the mixture was heated at reflux temperature for 15 minutes. The reaction mixture was allowed to cool and methanol was evaporated in vacuo. Water was added and the mixture was extracted with ethyl acetate. The organic extract was washed with a 5 % aqueous sodium bicarbonate solution, dried over sodium sulphate and the solvent evaporated in vacuo. This afforded 0.6 g (20 %) of 2-((3-((10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)oxy)-ethanol as an oil. TLC: r_f = 0.33 (SiO_2 ; n-heptane/ethyl acetate = 1:1).

A solution of the above alcohol (0.60 g, 2.0 mmol) in dry THF (15 ml) was placed under an atmosphere of nitrogen and then cooled on an ice-bath.

A solution of n-butyllithium in hexanes (0.88 ml, 2.5 M) was added dropwise at 10°C. When addition was complete the mixture was stirred at 10°C for 30 minutes. Methanesulfonyl chloride (0.25 g, 2.2 mmol) was added and the reaction mixture was stirred at room temperature for 90 minutes. The volatiles were evaporated in vacuo leaving a residue which was dissolved in acetone (20 ml). Ethyl (R)-3-piperidinecarboxylate (0.50 g, 3.0 mmol) and potassium carbonate (0.7 g, 5 mmol) were added and the suspension was stirred at room temperature for 16 h and then heated at reflux temperature for 7 h. The cooled reaction mixture was filtered and the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (150 g) using a mixture of ethyl acetate and n-heptane (2:3) as eluent. Collecting the proper fractions afforded 0.4 g of (R)-N-(2-((3-((10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)oxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil.

The above ester (0.4 g, 0.92 mmol) was dissolved in ethanol (10 ml) and a 4 N sodium hydroxide solution (0.70 ml) was added. The mixture was stirred at room temperature for 4 h. A 4 N hydrochloric acid solution was added until pH 1. Dichloromethane (300 ml) was added and the phases were separated. The organic phase was dried over sodium sulphate and the solvent was evaporated in vacuo. The residue was re-evaporated with acetone, dissolved in a mixture of ethyl acetate and acetone and left for crystallization. This afforded 0.13 g of the title compound as a solid.

10

M.P. 130-132°C. Calculated for $C_{25}H_{33}ClN_2O_3$:

C, 67.5%; H, 7.5%; N, 6.3%; Found:

C, 67.3%; H, 7.7%; N, 6.1%.

15

EXAMPLE 11

E/Z-(R)-N-(2-((((10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methylene)amino)oxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

20

A mixture of (10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)carboxaldehyde (11.5 g, 52 mmol, prepared similarly as described Acta Chem. Scand. B 1979, 33, 100) and hydroxylamine hydrochloride (7.2 g, 103 mmol) in 96% ethanol (50 ml) was stirred at room temperature for 2 days. A 10% aqueous citric acid solution (100 ml) was added together with ethyl acetate (100 ml). The phases were separated and the organic phase was washed successively with a 10% aqueous citric acid solution (50 ml), an excess of a saturated sodium bicarbonate solution and brine. The organic phase was dried over magnesium sulphate and the solvent was evaporated in vacuo to give a solid residue which was recrystallized from cyclohexane. This afforded 5.2 g of (10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)carboxaldehydoxime as a solid.

30

To an ice-cooled mixture of the above oxime derivative (5.4 g, 23 mmol), tetrabutylammonium bromide (0.73 g, 2.3 mmol) and 1,2-dibromoethane (19.6 ml) was added a 12 M sodium hydroxide solution (30 ml). The reaction mixture was stirred vigorously for 1.5 h.

5 The phases were separated and the aqueous phase was extracted with a small portion of toluene. The combined organic phases were diluted with another portion of toluene (50 ml) and washed successively with an aqueous citric acid solution (pH 6), an excess of a saturated sodium bicarbonate solution and brine. The organic phase was dried over mag-
10 nesium sulphate and the solvent was evaporated in vacuo to give an oily residue which was re-evaporated successively with methanol and dichloromethane. This afforded 7.8 g of the crude 2-(((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methyle-
ne)amino)oxy)ethylbromide as an oil. TLC: r_f = 0.62 (SiO₂; dichloromethane).
15

To a solution of the above crude bromide (7.0 g, 20 mmol) in acetone (100 ml) was added potassium carbonate (16.8 g, 122 mmol) and ethyl (R)-3-piperidinecarboxylate tartrate (12.5 g, 41 mmol) and the suspen-
20 sion was stirred at room temperature for 2.5 days. The solvent was evaporated in vacuo and the residue was dissolved in a mixture of ethyl acetate (100 ml) and water (100 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (50 ml). Water (100 ml) was added to the combined organic extracts and pH was adjusted to
25 4 with a 34% aqueous tartaric acid solution. The phases were separated and the organic phase was extracted with a 34% aqueous tartaric acid solution (3x18 ml). The three combined aqueous tartaric extracts were diluted with icewater (250 ml) and ethyl acetate was added (150 ml). A
30 4 N aqueous sodium hydroxide solution was added until pH 7 and the phases were separated. The organic phase was washed with a saturated sodium bicarbonate solution and brine. After drying over magnesium sulphate the solvent was evaporated in vacuo to give 6 g of

(R)-N-(2-((((10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)methylene)-amino)oxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: rf = 0.20 (SiO₂; ethyl acetate/n-heptane = 1:1).

5 The above ester (5.0 g, 12 mmol) was dissolved in ethanol (100 ml) and a 2 N aqueous sodium hydroxide solution (27 ml) was added. The mixture was stirred at room temperature for 16 h. The solvent was evaporated in vacuo to give an oily residue. Dichloromethane (160 ml) was added and the mixture was cooled on an ice-bath. A concentrated
10 hydrochloric acid solution (5.5 ml) was added. The mixture was stirred vigorously for a few minutes and the phases were separated. The organic phase was dried over magnesium sulphate and the solvent was evaporated in vacuo to give 4.1 g of the title compound as a foam. The material isolated consists of an approx. 1:5 mixture of the E/Z isomers.

15

M.P. 110°C.

¹H NMR (DMSO-d₆) δ Major isomer: 5.03 (d, 1H), 7.94 (d, 1H);

Minor isomer: 5.49 (d, 1H), 7.57 (d, 1H).

20

EXAMPLE 12

(R)-N-(2-(2-(5,6,7,12-Tetrahydrodibenz[b,g]azocin-12-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

25

To a solution of 5,6,7,12-tetrahydrodibenz[b,g]azocine (2.5 g, 12 mmol, prepared in a similar way as described in Chem. Pharm. Bull. 1978, 26, 942-950) and 2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethylchloride (3.0 g, 14 mmol) in toluene (50 ml) was added a suspension of sodium amide
30 (1.50 g, 19 mmol, 50% wt suspension in toluene). The reaction mixture was heated at reflux temperature for 10 h. The mixture was allowed to cool to room temperature and water (52.5 ml) was carefully added. The phases were separated and the aqueous phase was extracted with

toluene (50 ml). The combined organic phases were washed with water (2x15 ml), brine (15 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (150 g) using a mixture of ethyl acetate and n-heptane (1:4) as eluent. Collecting the proper fractions afforded 3.0 g of crude 12-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-5,6,7,1-2-tetrahydrodibenz[b,g]azocine. TLC: $r_f = 0.11$ (SiO_2 ; ethyl acetate/-n-heptane = 1:4).

To a solution of 12-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-5,6,7,12-tetrahydrodibenz[b,g]azocine (3.0 g, 7.8 mmol) in (30 ml) was added a 4 M aqueous sulfuric acid solution. The mixture was stirred at room temperature for 18 h. The reaction mixture was poured into a mixture of water (150 ml) and a 4 M aqueous sodium hydroxide solution (6.5 ml). Ethyl acetate (100 ml) was added and pH was adjusted to 8.5 with a 5% aqueous sodium bicarbonate solution. The phases were separated and the aqueous phase was extracted with ethyl acetate (50 ml). The combined organic phases were washed with brine (20 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo and the residue was re-evaporated with dichloromethane. This afforded 2.1 g of crude 2-(2-(5,6,7,12-tetrahydrodibenz[b,g]azocin-12-yl)ethoxy)ethanol. TLC: $r_f = 0.39$ (SiO_2 ; dichloromethane/methanol = 19:1).

A mixture of the above alcohol (1.8 g, 6 mmol), triethylamine (2.5 ml) and toluene (30 ml) placed under an atmosphere of nitrogen was cooled on an ice-bath. A solution of methanesulfonyl chloride (1.7 g, 12 mmol) in toluene (5 ml) was added dropwise. Stirring was continued for 45 minutes on an ice-bath and then the temperature was allowed to reach ambient temperature. Water (20 ml) was added and the mixture was stirred at room temperature for 15 minutes. The phases were separated and the aqueous phase was extracted with toluene (20 ml). The combined organic phases were washed with a 5% aqueous sodium bicarbon-

ate solution and dried over magnesium sulphate. The solvent was evaporated in vacuo to give an oil which was dissolved in toluene (30 ml). To this solution was added potassium carbonate (2.9 g, 21 mmol) and ethyl (R)-3-piperidinecarboxylate tartrate (3.7 g, 12 mmol). The suspension was heated at 100°C for 24 h and then allowed to cool to ambient temperature. The mixture was filtered and the solid washed with toluene (20 ml). The solvent was evaporated in vacuo to give an oily residue which was submitted to column chromatography on silica gel (150 g) using a gradient of a mixture of ethyl acetate and n-heptane (1:4 - 1:1). Collecting the proper fractions afforded 1.27 g of (R)-N-(2-(2-(5,6,7,12-tetrahydrodibenz[b,g]azocin-12-yl)-ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: r_f = 0.39 (SiO_2 ; dichloromethane/ methanol/acetic acid = 20:2:1).

The above ester (1.2 g, 2.7 mmol) was dissolved in ethanol (5 ml). A 4 N aqueous sodium hydroxide solution (2 ml) and water (3 ml) were added. The mixture was heated at 50°C with stirring for 1 h. Water (25 ml) was added and ethanol was evaporated in vacuo. The aqueous residue was extracted with diethyl ether (2x25 ml) which was discarded. Then a 4 N aqueous hydrochloric acid solution (3 ml) was added to the aqueous phase and the resulting acidic solution was extracted with dichloromethane (2x50 ml). From the combined dichloromethane extracts the solvent was evaporated in vacuo and the residue re-evaporated with acetone. The foamy residue was triturated with diethylether to give 0.71 g of an amorphous solid which was recrystallized from 2-propanol (35 ml). After drying in vacuo 0.45 g of the title compound was obtained as a white solid.

M.P. 203.5-205.5°C. Calculated for $\text{C}_{25}\text{H}_{33}\text{ClN}_2\text{O}_3$:
C, 67.5%; H, 7.5%; N, 6.3%; Cl, 8.0% Found:
C, 67.5%; H, 7.7%; N, 6.0%; Cl, 7.9%.

EXAMPLE 13

(R)-N-(2-(2-(6,11-Dihydro-5H-dibenz[b,e]azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid formate

To a solution of 6,11-dihydro-5H-dibenz[b,e]azepine (5.0 g, 26 mmol, Coll. Czechoslov. Chem. Commun. 1958, 23, 1330) and 2-(2-((tetrahydro-2pyranyl)oxy)ethoxy)ethylchloride (6.4 g, 30 mmol) in toluene (25 ml) placed under an atmosphere of nitrogen was added a suspension of sodium amide (5.0 g, 64 mmol, 50% wt suspension in toluene). The reaction mixture was heated at reflux temperature for 8 h. The mixture was allowed to cool to room temperature and toluene (50 ml) was added. The phases were separated and the organic phase was washed with a 1 N aqueous hydrochloric acid solution (2x100 ml), excess of a 5 % aqueous sodium bicarbonate solution and brine (25 ml). After drying over magnesium sulphate the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel (250 g) using a mixture of ethyl acetate and n-heptane (1:4) as eluent. Collecting the proper fractions afforded 2.6 g of 12-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-6,11-dihydro-5H-dibenz[b,e]azepine. TLC: $r_f = 0.41$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

To a solution of 12-(2-(2-((tetrahydro-2-pyranyl)oxy)ethoxy)ethyl)-6,11-dihydro-5H-dibenz[b,e]azepine (2.9 g, 7.9 mmol) in 2-propanol (30 ml) was added a 4 M aqueous sulfuric acid solution (6 ml). The mixture was stirred at room temperature for 1 h. The reaction mixture was poured into a mixture of water (100 ml) and toluene (25 ml). The phases were separated and the organic phase was washed with excess of a saturated aqueous sodium bicarbonate solution. The acidic aqueous phase was made alkaline with aqueous sodium hydroxide and extracted with toluene. The combined organic phases were washed with brine and dried

over magnesium sulphate. The solvent was evaporated in vacuo to give 2.2 g of crude 2-(2-(6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)ethoxy)-ethanol. TLC: $r_f = 0.17$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

5 A mixture of the above alcohol (2.1 g, 7.4 mmol), triethylamine (2.6 ml) and toluene (30 ml) placed under an atmosphere of nitrogen was cooled on an ice-bath. A solution of methanesulfonyl chloride (2.1 g, 15 mmol) in toluene (5 ml) was added dropwise. Stirring was continued for 45 minutes on an ice-bath and then the temperature was allowed to reach
10 ambient temperature. Water (20 ml) was added and the mixture was stirred at room temperature for 15 minutes. The phases were separated and the organic phases were washed with a 5% aqueous sodium bicarbonate solution and brine and dried over magnesium sulphate. The solvent was evaporated in vacuo to give an oil which was dissolved in
15 methyl isobutylketone (40 ml). To this solution was added potassium carbonate (3.6 g, 26 mmol) and ethyl (R)-3-piperidinecarboxylate tartrate (4.6 g, 15 mmol). The suspension was heated at 40°C for 24 h and then at reflux temperature for 3 h. The reaction mixture was allowed to cool to ambient temperature and water (50 ml) was added. The phases were
20 separated and from the organic phase the solvent was evaporated in vacuo. This afforded an oily residue which was submitted to column chromatography on silica gel (125 g) using a mixture of ethyl acetate and n-heptane (1:1) as eluent. Collecting the proper fractions afforded 1.0 g of (R)-N-(2-(2-(6,11-dihydro-5H-dibenz[b,e]azepin-5-yl)-
25 ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.36$ (SiO_2 ; ethyl acetate).

The above ester (1.0 g, 2.4 mmol) was dissolved in ethanol (25 ml) and a 2 N aqueous sodium hydroxide solution (4.7 ml) was added. The
30 mixture was heated at 50°C with stirring for 2.5 h. The volatiles were evaporated in vacuo and dichloromethane (100 ml) was added to the residue. The mixture was cooled on an ice-bath and a concentrated

aqueous hydrochloric acid solution (1.2 ml) was added dropwise with vigorous stirring. The phases were separated and the organic phase was dried over magnesium sulphate. The solvent was evaporated in vacuo and the residue re-evaporated several times with acetone.

5

The residue was purified by column chromatography on silica gel using a mixture of dichloromethane, acetonitrile and formic acid (4:4:1) as eluent. The proper fractions were collected and the solvent was evaporated in vacuo to give a residue which was re-evaporated successively with n-heptane, dioxane and dichloromethane. This afforded 0.4 g of the title compound as a waxy solid.

10

¹H NMR (DMSO-d₆) δ 4.13 (m, 1H); 4.67 (m, 1H).

15

EXAMPLE 14

(R)-N-(2-(2-(5,6,11,12-Tetrahydrodibenz[b,f]azocin-12-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid hydrochloride

20

To a solution of 2-(2-chloroethoxy)ethanol (3.9 g, 31 mmol) in dichloromethane (15 ml) kept at 0°C was added triethylamine (6.2 g, 61 mmol). A solution of methanesulfonyl chloride (3.6 g, 31 mmol) in dichloromethane (15 ml) was carefully added keeping the temperature below 0°C. When addition was complete the reaction mixture was left overnight at room temperature and then diluted with dichloromethane (150 ml). The organic phase was washed with a 2 N hydrochloric acid solution (75 ml) and water (75 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo to give 6.3 g of crude 2-(2-chloroethoxy)ethyl mesylate as an oil.

25

30

A suspension of 5,6,11,12-tetrahydrodibenz[b,f]azocine (5.0 g, 20 mmol) in dry THF (75 ml) placed under an atmosphere of nitrogen was cooled to -68°C. A solution of n-butyl lithium in hexanes (19 ml, 49

mmol, 2.5 M) was added dropwise keeping the temperature below -60°C. When addition was complete stirring was continued at this temperature for 30 minutes and then the reaction mixture was left overnight at room temperature. The mesylate prepared above was dissolved in dry THF (50 ml) and added dropwise to the reaction mixture. When addition was complete the mixture was stirred at room temperature for 168 h. Ice was added (80 g) and the phases were separated. The aqueous phase was extracted with diethyl ether (2x50 ml). The combined organic phases were washed with water (2x50 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo to give a residue which was submitted to column chromatography on silica gel using a mixture of ethyl acetate and n-heptane (2:3) as eluent. This afforded 2.5 g of 2-(2-(5,6,11,12-tetrahydrodibenz[b,f]azocin-12-yl)ethoxy)ethylchloride as an oil.

A mixture of the above chloride (2.5 g, 7.9 mmol), ethyl (R)-3-piperidinecarboxylate tartrate (2.4 g, 16 mmol) and potassium carbonate (3.3 g, 24 mmol) in methylisobutyl ketone (60 ml) was heated at reflux temperature for 96 h. The mixture was allowed to cool and the solvent was evaporated in vacuo. The residue was dissolved in a mixture of ethyl acetate (75 ml) and water (75 ml). The phases were separated and from the organic phase the solvent was evaporated in vacuo. The oily residue was submitted to column chromatography on silica gel using dichloromethane containing 5% of a mixture of ethanol and 25% aqueous ammonia (9:1) as eluent. The proper fractions were collected and the solvent was evaporated in vacuo. The residue was submitted once more to column chromatography on silica gel using dichloromethane containing 3% of a mixture of ethanol and 25% aqueous ammonia (9:1) as eluent. The proper fractions were collected and the solvent was evaporated in vacuo to give 0.85 g of (R)-N-(2-(2-(5,6,11,12-tetrahydrodibenz[b,f]azocin-12-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil.

The above ester (0.4 g, 0.9 mmol) was dissolved in ethanol (7 ml) and a 2 N aqueous sodium hydroxide solution (1.8 ml) was added. The reaction mixture was stirred at room temperature for 16 h. The mixture was placed on an ice-bath and a concentrated aqueous hydrochloric acid solution (0.37 ml) was added. The volatiles were evaporated in vacuo, the residue suspended in dichloromethane and the solid removed by filtration. The solvent was evaporated from the filtrate in vacuo to give a residue which was re-evaporated with dichloromethane to give 0.30 g of the title compound as an amorphous solid.

M.P. 60-80°C. Calculated for $C_{25}H_{33}ClN_2O_3 \cdot \frac{1}{4}CH_2Cl_2$:
C, 65.1%; H, 7.2%; N, 6.0%; Found:
C, 65.2%; H, 7.1%; N, 6.0%.

EXAMPLE 15

N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride

To a solution of 2-(2-chloroethoxy)ethanol (15.3 g, 123 mmol) in toluene (100 ml) kept at 5°C was added triethylamine (50 g, 500 mmol). A solution of methanesulfonyl chloride (28 g, 245 mmol) in toluene (50 ml) was carefully added keeping the temperature around 5°C. When addition was complete the reaction mixture was stirred at 5°C for 45 minutes and then 75 minutes at ambient temperature. Water (100 ml) was added and the mixture was stirred for 15 minutes. The phases were separated and the organic phase was washed with water, brine and dried over magnesium sulphate. The solvent was evaporated in vacuo to give crude 2-(2-chloroethoxy)ethyl mesylate as an oil.

A solution of 10,11-dihydro-5H-dibenz[b,f]azepine (24 g, 123 mmol) in dry THF (100 ml) placed under an atmosphere of nitrogen was cooled to

-70°C. A solution of n-butyl lithium in hexanes (49.2 ml, 123 mmol, 2.5 M) was added dropwise keeping the temperature below -60°C. When addition was complete stirring was continued at -70°C for 15 minutes and then the reaction mixture was allowed to reach ambient temperature. The mesylate prepared above was dissolved in dry THF (50 ml) and added dropwise to the reaction mixture. When addition was complete the mixture was stirred at room temperature for 64 h. Water (100 ml) was added and the phases were separated. The aqueous phase was extracted with diethyl ether (50 ml). The combined organic phases were washed with brine and dried over magnesium sulphate. The solvent was evaporated in vacuo to give an oily residue which was submitted to column chromatography on silica gel (300 g, Lichroprep. 40-63 μ) using a mixture of dichloromethane and n-heptane (1:5) as eluent. This afforded 10.4 g of 2-(2-(10,11-dihydro-5H-dibenz[b,f]-azepin-5-yl)ethoxy)ethylchloride as an oil. TLC: r_f = 0.23 (SiO_2 ; dichloromethane/n-heptane = 1:1).

A mixture of the above chloride (5.0 g, 16.6 mmol), ethyl 1,2,5,6-tetrahydro-3-pyridinecarboxylate hydrochloride (6.3 g, 33 mmol), potassium carbonate (8.0 g, 58 mmol) and potassium iodide (0.55 g) in methylisobutyl ketone (50 ml) was heated at reflux temperature for 48 h. The reaction mixture was allowed to cool and water (50 ml) was added. The phases were separated and from the organic phase the solvent was evaporated in vacuo to give an oily residue. This residue was dissolved in a mixture of ethyl acetate (50 ml) and water (50 ml) and pH was adjusted to 4 with a 34% aqueous tartaric acid solution. The phases were separated and the organic phase was extracted with a 34% aqueous tartaric acid solution (3x15 ml). The three aqueous tartaric extracts were combined and icewater (150 ml) and ethyl acetate (100 ml) was added. A 12 N aqueous sodium hydroxide solution was added until pH 4 and the phases were separated. The organic phase was washed with a 5% sodium bicarbonate solution and brine and dried over magnesium sul-

phate. The solvent was evaporated in vacuo to give 6.0 g of
N-(2-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-
ethoxy)ethyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid ethyl ester as
an oil. TLC: r_f = 0.47 (SiO_2 ; dichloromethane/methanol/acetic acid =
20:2:1).

The above ester (5.0 g, 12 mmol) was dissolved in ethanol (250 ml) and
a 2 N aqueous sodium hydroxide solution (24 ml) was added. The
mixture was stirred at room temperature for 16 h. The solvent was
evaporated in vacuo to give an oily residue. Dichloromethane (200 ml)
was added and the mixture was cooled on an ice-bath. A concentrated
hydrochloric acid solution (5.9 ml) was added. The mixture was stirred
vigorously for a few minutes and the phases were separated. The
organic phase was dried over magnesium sulphate and the solvent was
evaporated in vacuo to give an oily residue which was re-evaporated
with acetone. This afforded 4.8 g of the title compound as a foam.

M.P. 103°C. Calculated for $\text{C}_{24}\text{H}_{29}\text{ClN}_2\text{O}_3 \cdot \text{H}_2\text{O}$:

C, 64.5%; H, 6.5%; N, 6.3%; Found:

C, 64.9%; H, 6.9%; N, 5.9%.

^1H NMR ($\text{DMSO}-d_6$) δ 3.53 (t, 2H); 3.95 (t, 2H); 6.96 (brs, 1H).

EXAMPLE 16

N-(2-(2-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-pyrroli-
dineacetic acid hydrochloride

A mixture of 2-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl-
chloride (1.5 g, 4.9 mmol, prepared as described in Example 15), methyl
3-pyrrolidineacetate acetate (2.0 g, 9.8 mmol), potassium carbonate (2.4
g, 17 mmol) and potassium iodide (0.16 g) in methylisobutyl ketone (30
ml) was heated at reflux temperature for 48 h. The reaction mixture was

allowed to cool and water (40 ml) was added. The phases were separated and from the organic phase the solvent was evaporated in vacuo to give an oily residue. This residue was dissolved in a mixture of ethyl acetate (25 ml) and water (25 ml) and pH was adjusted to 4 with a 34% aqueous tartaric acid solution. The phases were separated and the organic phase was discarded. Ethyl acetate (25 ml) was added to the aqueous phase and pH was adjusted to approx. 9 with a 2 M aqueous sodium hydroxide solution. The phases were separated and from the organic phase the solvent was evaporated in vacuo to give an oily residue which was submitted to column chromatography on silica gel (180 ml) using a mixture of THF and n-heptane (1:1) as eluent. Collecting the proper fraction afforded 1.0 g of N-(2-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)ethyl)-3-pyrrolidine-acetic acid methyl ester as an oil.

The above ester (1.0 g, 2.5 mmol) was dissolved in ethanol (25 ml) and a 2 N aqueous sodium hydroxide solution (4.9 ml) was added. The mixture was stirred at room temperature for 16 h. The solvent was evaporated in vacuo to give an oily residue. Dichloromethane (100 ml) was added and the mixture was cooled on an ice-bath. A concentrated hydrochloric acid solution (1 ml) was added dropwise. The mixture was stirred vigorously for 15 minutes at approx. 10°C. Magnesium sulphate was added and the mixture was stirred at ambient temperature for 30 minutes and filtered. The solvent was evaporated in vacuo to give 0.9 g of the title compound as a foam.

M.P. 138°C. Calculated for $C_{24}H_{31}ClN_2O_3$:

C, 66.9%; H, 7.3%; N, 6.5%; Found:

C, 66.8%; H, 7.4%; N, 6.2%.

1H NMR (DMSO- d_6) δ 3.54 (t, 2H); 3.94 (t, 2H).

EXAMPLE 17

(R)-N-(2-(2-(3,7-Dichloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)ethoxy)-ethyl)-3-piperidinecarboxylic acid hydrochloride

To a solution of 3,7-dichloro-10,11-dihydro-5H-dibenz[b,f]azepine (2.0 g, 7.6 mmol, prepared as described in British Patent No. 777,546)) in dry dimethylsulfoxide (20 ml) placed under an atmosphere of nitrogen was added sodium hydride (0.36 g as a 55 % oil dispersion, 8.3 mmol). The reaction mixture was stirred at 70°C for 1 h and then allowed to cool to ambient temperature. 2-(2-((Tetrahydro-2-pyran-yl)oxy)ethoxy)ethylchloride (1.7 g, 8.3 mmol) was added and the mixture was stirred at room temperature for two days. The reaction mixture was poured into icewater and extracted with ethyl acetate (2x200 ml). The combined organic extracts were washed with water and dried over magnesium sulphate. The solvent was evaporated in vacuo to give 3.7 g of an oil which was dissolved in methanol (100 ml). A 4 N aqueous hydrochloric acid solution (30 ml) was added and the mixture was stirred at 50°C for 1 h. The cooled reaction mixture was diluted with water (700 ml) and extracted with ethyl acetate (2x200 ml). The combined organic extracts were washed with a saturated aqueous sodium bicarbonate solution and dried over magnesium sulphate. The solvent was evaporated in vacuo to give an oily residue which was submitted to column chromatography on silica gel (100 g) using a mixture of ethyl acetate and n-heptane (3:7) as eluent. Collecting the proper fractions afforded 1.3 g of 2-(2-(3,7-dichloro-10,11-dihydro-5H--dibenz[b,f]azepin-5-yl)ethoxy)ethanol as an oil. TLC: r_f = 0.32 (SiO_2 ; ethyl acetate/n-heptane = 1:1).

To a mixture of the above alcohol (1.3 g, 3.7 mmol), triethylamine (1.3 ml) and dry diethyl ether (75 ml) was added dropwise a solution of methanesulfonyl chloride (0.63 g, 5.5 mmol) in dry diethyl ether (25 ml).

Stirring was continued for 1 h at room temperature. The reaction mixture was washed with water and dried over potassium carbonate. The solvent was evaporated in vacuo to give an oily residue which was dissolved in acetone (30 ml). To this solution was added potassium carbonate (1.0 g, 7.4 mmol) and ethyl (R)-3-piperidinecarboxylate (1.2 g, 7.4 mmol) and the suspension was heated at reflux temperature for 16 h. Another portion of ethyl (R)-3-piperidinecarboxylate (0.5 g) was added and the mixture was heated at reflux temperature for 24 h. The cooled reaction mixture was filtered and from the filtrate the solvent was evaporated in vacuo. This afforded an oil which was submitted to column chromatography on silica gel (100 g) using a mixture of ethyl acetate and n-heptane (1:1) as eluent. Collecting the proper fractions gave 1.5 g of (R)-N-(2-(2-(3,7-dichloro-10,11-dihydro-5H-dibenz[b,f]-azepin-5-yl)ethoxy)ethyl)-3-piperidinecarboxylic acid ethyl ester as an oil. TLC: $r_f = 0.18$ (SiO_2 ; ethyl acetate/n-heptane = 1:1).

The above ester (1.5 g, 3.1 mmol) was dissolved in ethanol (20 ml). A 4 N aqueous sodium hydroxide solution (2.3 ml) was added and the mixture was stirred at ambient temperature for 3 h. A concentrated aqueous hydrochloric acid solution (3 ml) was added until pH 1 and the mixture was extracted with dichloromethane (300 ml). The phases were separated and the organic phase was washed with water (10 ml) and dried over magnesium sulphate. The solvent was evaporated in vacuo and the residue re-evaporated with acetone. The foamy residue was dissolved in acetone (20 ml) and left for crystallization. This afforded 1.25 g of the title compound as a solid.

M.P. 213-214°C. Calculated for $\text{C}_{24}\text{H}_{29}\text{Cl}_2\text{N}_2\text{O}_3$:
C, 57.7%; H, 5.9%; N, 5.6%; Found:
C, 57.6%; H, 6.1%; N, 5.6%.

EXAMPLE 18

(R)-N-(3-(2-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)-1-propyl)-3-piperidinecarboxylic acid hydrochloride

5

A mixture of 5-(ethylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (4.0 g, 18 mmol, prepared similar as described in J. Med. Chem. 1990, 33, 3095), dibenzoyl peroxide (60 mg), N-bromosuccinimide (3.2 g, 18 mmol) and carbontetrachloride (20 ml) was heated at reflux temperature for 18 h. N-bromosuccinimide (1.6 g, 9 mmol) was added and the mixture was heated at reflux temperature for 24 h. The mixture was allowed to cool and then filtered through silica gel (50 ml) and the gel was washed with dichloromethane (150 ml). From the combined filtrate and washing the solvents were evaporated in vacuo to give 6.85 g of an oil. A solution of n-butyllithium (6.7 ml, 16.7 mmol, 2.5 M) was added dropwise to ice-cooled propylene glycol (100 ml) under an atmosphere of nitrogen. When addition was complete the mixture was stirred at room temperature for 90 minutes. A solution of the crude bromide prepared above (5 g) dissolved in toluene (50 ml) was added and the mixture was stirred at room temperature for 3 days. The mixture was diluted with water (100 ml) and the phases were separated. The aqueous phase was extracted with toluene (2 x 50 ml). The combined organic extracts were washed with water (50 ml), brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue which was submitted to column chromatography on silica gel (225 g) using a mixture of THF and n-heptane (3:7) as eluent. Collecting the proper fractions afforded 0.6 g of 3-(2-(5H-dibenzo[a,d]cyclohepten-5-ylidene)ethoxy)-1-propanol as an oil.

30

A mixture of the above alcohol (0.6 g, 2.0 mmol) and triethylamine (0.52 g, 5.1 mmol) in toluene (10 ml) was placed on an ice-bath under an atmosphere of nitrogen. A solution of methanesulfonyl chloride (0.59 g, 4.1 mmol) in toluene (1.5 ml) was added keeping the temperature

below 10°C. When addition was complete the mixture was stirred for 45 minutes at 5°C and 30 minutes below 15°C. Water was added (5 ml) and the mixture was stirred at ambient temperature for 15 minutes. The phases were separated and the aqueous phase was extracted with toluene (5 ml). The combined organic phases were washed with a 5 % aqueous sodium bicarbonate solution, brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give a residue which was dissolved in toluene (10 ml). Ethyl (R)-3-piperidinecarboxylate tartrate (1.25 g, 4.1 mmol) and potassium carbonate (0.98 g, 7.1 mmol) was added and the mixture was heated at reflux temperature for 16 h. The mixture was allowed to cool and then filtered. The solvent was evaporated from the filtrate leaving an oil which was dissolved in ethyl acetate (20 ml). Water (20 ml) was added and pH was adjusted to 4 with a 34 % aqueous tartaric acid solution. The phases were separated and the aqueous phase was extracted with ethyl acetate (10 ml). The organic phases were combined and washed with excess of a 5 % aqueous sodium bicarbonate solution, brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give an oil which was re-evaporated successively with methanol and dichloromethane. This afforded 0.77 g of an oil which was dissolved in toluene (15 ml) and extracted with a 34 % aqueous tartaric acid solution (15 + 7 ml). The combined aqueous extracts were washed with toluene (5 ml) and the toluene phases were discarded. The acidic aqueous phase was diluted with water (30 ml) and ethyl acetate (50 ml) was added. A 4 N aqueous sodium hydroxide solution (12 ml) and excess of a 5 % aqueous sodium bicarbonate solution was added. The phases were separated and the aqueous phase was extracted with ethyl acetate (30 ml). The combined ethyl acetate extracts were washed with brine and dried over sodium sulphate. The solvent was evaporated in vacuo to give an oil which was re-evaporated successively with methanol and dichloromethane. This afforded 0.42 g of (R)-N-(3-(2-(5H-dibenzo[a,d]-cyclohepten-5-ylidene)-ethoxy)-1-propyl)-3-piperidinecarboxylic acid ethyl ester as an oil.


The above ester (0.42 g, 1.0 mmol) was dissolved in ethanol (5 ml) and a 12 N aqueous sodium hydroxide solution (0.36 ml) was added. The mixture was stirred at room temperature for 3.5 h and the solvent was evaporated in vacuo to give an oily residue. Dichloromethane (30 ml) was added and the mixture was cooled on an ice-bath. A concentrated hydrochloric acid solution (0.45 ml) was added dropwise and a small amount of icewater was added to dissolve the solid formed. The phases were separated and the organic phase was dried over sodium sulphate. The solvent was evaporated in vacuo to give an oily residue which was re-evaporated with dichloromethane. This afforded 0.43 g of the title compound as an amorphous solid.

M.P. 114-119°C.

¹H NMR (DMSO-d₆) δ 3.77 (dd, 1H); 4.08 (dd, 1H); 5.63 (dd, 1H); 6.90-6.97 (m, 2H).

CLAIMS

1. The use of a compound of the general formula I



wherein

- 15 R¹ and R² independently are hydrogen, halogen, trifluoromethyl, C₁₋₆-alkyl or C₁₋₆-alkoxy; Y is $\text{>}\underline{\text{N}}\text{-CH}_2\text{-}$, $\text{>}\underline{\text{CH}}\text{-CH}_2\text{-}$ or $\text{>}\underline{\text{C}}\text{=CH-}$ when s is 0, 1 or 2 or Y is $\text{>}\underline{\text{CH}}\text{-CH=N-}$ or $\text{>}\underline{\text{C}}\text{=N-}$ when s is 0 wherein only the under-scored atom participates in the ring system;

X is -0-;

- 20 Z is -O-, -S-, -CH₂-, -CH₂CH₂-, -CH=CH-CH₂-, -CH₂-CH=CH-, -CH₂CH₂CH₂-, -CH=CH- or -O-CH₂-;

R⁴ and R⁵ each represents hydrogen or may when m is 2 together represent a bond;

R⁶ is OH or C₁₋₈-alkoxy;

- 25 p is 0 or 1;
 q is 0 or 1;
 s is 0, 1 or 2;
 r is 2, 3 or 4;
 m is 1 or 2;

- 30 n is 1 when m is 1 or n is 0 when m is 2; or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for reducing blood glucose and/or inhibit the activity of CGRP.

2. The use according to claim 1 wherein R¹ and R² independently are hydrogen, halogen or trifluoromethyl.

3. The use according to claim 1 or 2 wherein Z is -O-, -S-, -CH₂-,
5 -(CH₂)₂-, -(CH₂)₃- or -CH=CH-.

4. The use according to any one of the preceding claims wherein R⁶ is OH.

10 5. The use according to any one of the preceding claims wherein m is 1.

6. The use according to any one of the preceding claims wherein m is 2.

15

7. The use according to any one of the preceding claims wherein said composition is in a form suitable for oral administration.

8. The use according to any one of the preceding claims wherein
20 said compound is administered as a dose in a range from about 0.5 to 1000, preferably in the range from about 1 to 500 and especially in the range from about 50 to 200 mg/pr. day.

9. The use according to any one of the preceding claims wherein
25 the treatment is related to insulin resistance in NIDDM.

10. The use according to any one of the preceding claims wherein the treatment is related to insulin resistance in aging.

30 11. A method for reducing blood glucose and/or inhibit the activity of CGRP comprising administering to a patient a clinically effective amount of a compound of formula I as stated in claim 1 or a pharmaceutically

acceptable salt thereof.

12. A method according to the previous claims wherein R¹ and R² independently are hydrogen, halogen or trifluoromethyl.

5

13. A method according to any one of the preceding method claims wherein Z is -O-, -S-, -CH₂-, -(CH₂)₂-, -(CH₂)₃- or -CH=CH-.

14. A method according to any one of the preceding method claims wherein R⁶ is OH.

10

15. A method according to any one of the preceding method claims wherein m is 1.

16. A method according to any one of the preceding method claims wherein m is 2.

15

17. A method according to any one of the preceding method claims wherein said compound is administered as a dose in a range from about 0.5 to 1000, preferably in the range from about 1 to 500 and especially in the range from about 50 to 200 mg/pr. day.

20

18. A method according to any one of the preceding method claims wherein the treatment is related to insulin resistance in NIDDM.

25

19. A method according to any one of the preceding method claims wherein the treatment is related to insulin resistance in aging.

30

20. A method for reducing blood glucose and/or inhibit the activity of CGRP which method comprises administering a clinically effective amount of a compound of formula I or a salt thereof and a pharmaceutically acceptable composition containing such a compound, to a patient in

need of such treatment.

21. Any novel feature or combination of features described herein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00520

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/445, A61K 31/535, A61K 31/54, A61K 31/41
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9220658 A1 (NOVO NORDISK A/S), 26 November 1992 (26.11.92)	1-10
	--	
A	WO 9518615 A1 (NOVO NORDISK A/S), 13 July 1995 (13.07.95)	1-10
	-- -----	

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 February 1997

Date of mailing of the international search report

07 -03- 1997

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer
Göran Karlsson
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00520

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 11-20
because they relate to subject matter not required to be searched by this Authority, namely:
A method for treatment of the human or animal body by therapy, see rule 39.1
2. ☒ Claims Nos.: 21
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 21 does not clearly define the matter for which protection is sought, see Article 6.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 96/00520

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9220658	26/11/92	AT-T- 143009	15/10/96
		AU-B- 665761	18/01/96
		AU-A- 1783792	30/12/92
		CA-A- 2102811	18/11/92
		DE-D- 69213935	00/00/00
		EP-A,B- 0585314	09/03/94
		ES-T- 2094357	16/01/97
		FI-D- 935064	00/00/00
		JP-T- 6507616	01/09/94
		NO-A- 934159	17/11/93
		NZ-A- 242759	28/03/95
		US-A- 5348965	20/09/94
WO-A1- 9518615	13/07/95	AU-A- 1311195	01/08/95
		EP-A- 0735872	09/10/96
		FI-A- 962750	04/09/96
		HU-D- 9601826	00/00/00
		IL-D- 112223	00/00/00
		NO-A- 962812	04/09/96
		ZA-A- 9500030	04/07/96